Farmakoterapia w Psychiatrii i Neurologii

Pełna treść

2/2024 vol. 40
Artykuł przeglądowy

Nowe grupy leków neuroleptycznych – inhibitory fosfodiesterazy 10A. Przegląd narracyjny

Tadeusz Pietras 1
,
Kasper Sipowicz 1
,
Marcin Kosmalski 2
  1. Geriatrics Clinic and Polyclinic, National Geriatrics, Rheumatology and Rehabilitation Institute, Poland; Klinika i Poliklinika Geriatrii, Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher, Warszawa, Polska
  2. Department Clinical Pharmacology, Medical University of Lodz, Poland; Zakład Farmakologii Klinicznej, Uniwersytet Medyczny w Łodzi, Polska
Farmakoterapia w Psychiatrii i Neurologii 2024, 40 (2), 119–126
DOI: https://doi.org/10.5114/fpn.2024.147495
Data publikacji online: 2025/03/31
Plik artykułu
4E0_IPiN_FARM_2024-2D.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Akinola PS, Tardif I, Leclerc J. Antipsychotic-Induced Metabolic Syndrome: A Review. Metab Syndr Relat Disord. 2023; 21: 294-305.
  2. Amin HS, Parikh PK, Ghate MD. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors – An update of recent progress. Eur J Med Chem. 2021; 214: 113155.
  3. Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev. 2005; 2005 (1): CD002230.
  4. Arakawa K, Maehara S, Yuge N, Ishikawa M, Miyazaki Y. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potential for the treatment of schizophrenia. Pharmacol Res Perspect. 2016; 4 (4): e00241.
  5. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013; 54: 1-13.
  6. Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M et al. Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals (Basel). 2021; 14: 238.
  7. Chappie TA, Helal CJ, Hou X. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J Med Chem. 2012; 55: 7299-331.
  8. Chappie TA, Humphrey JM, Allen MP, Estep KG, Fox CB, et al. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J Med Chem. 2007; 50: 182-5.
  9. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006 ;54: 1205-13.
  10. Charych EI, Jiang L-X, Lo F, Sullivan K, Brandon NJ. Interplay of Palmitoylation and Phosphorylation in the Trafficking and Localization of Phosphodiesterase 10A: Implications for the Treatment of Schizophrenia. J Neurosci 2010; 30: 9027–37.
  11. Dias MF, Nogueira YJA, Romano-Silva MA, Marques de Miranda D. Effects of antipsychotics on the gastrointestinal microbiota: A systematic review. Psychiatry Res. 2024; 336: 115914.
  12. Francis SH, Sekhar KR, Ke H, Corbin JD. Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. Handb Exp Pharmacol. 2011; (200): 93-133.
  13. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi SI, et al. (1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999; 274: 18438-45.
  14. García AM, Redondo M, Martinez A, Gil C. Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson’s disease? Curr Med Chem. 2014; 21(10): 1171-87.
  15. Gomes DA, Joubert AM, Visagie MH. The Biological Relevance of Papaverine in Cancer Cells. Cells. 2022; 11: 3385.
  16. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009; 331: 574-90.
  17. Harada A, Suzuki K, Kamiguchi N, Miyamoto M, Tohyama K. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor. PLoS One. 2015; 10: e0122197.
  18. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017; 4: 295-301.
  19. Kaczor AA, Silva AG, Loza MI, Kolb P, Castro M, et al. Structure-Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics. ChemMedChem. 2016; 11: 718-29.
  20. Kantrowitz JT. Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions. CNS Drugs. 2021; 35 (11): 1153-61.
  21. Kotera J, Sasaki T, Kobayashi T, Fujishige K, Yamashita Y, Omori K. Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation. J Biol Chem. 2004; 279: 4366-75.
  22. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010; 59 (6): 367-74.
  23. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005; 365: 167-75.
  24. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, et al. (1999). Isolation and characterization of PDE10A, a novel human 3’, 5’-cyclic nucleotide phosphodiesterase. Gene 1999; 234: 109-17.
  25. MacMullen CM, Vick K, Pacifico R, Fallahi-Sichani M, Davis RL. Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder. Transl Psychiatry 2016; 6: e742.
  26. Martin C, Burgel PR, Roche N. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. Int J Chron Obstruct Pulmon Dis. 2021; 16: 2363-2373.
  27. Matloka M, Janowska S, Pankiewicz P, Kokhanovska S, Kos T, et al. A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. Front Pharmacol. 2022; 13: 999685.
  28. Megens AA, Hendrickx HM, Hens KA, Fonteyn I, Langlois X, et al. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs. J Pharmacol Exp Ther. 2014; 349: 138-54.
  29. Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev. 2009; 14: 255-63.
  30. Mukai Y, Lupinacci R, Marder S, et al. Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial. Schizophr Res. 2024; 270: 37-43.
  31. Paronetto MP, Crescioli C. Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health. Front Endocrinol (Lausanne). 2024; 15: 1461642.
  32. Polito M, Guiot E, Gangarossa G, Longueville S, Doulazmi M, et al. Selective Effects of PDE10A Inhibitors on Striatopallidal Neurons Require Phosphatase Inhibition by DARPP-32. eNeuro. 2015; 2: ENEURO.0060-15.2015
  33. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003; 985: 113-26.
  34. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008; 325: 681-90.
  35. Schudt C, Hatzelmann A, Beume R, Tenor H. Phosphodiesterase inhibitors: history of pharmacology. Handb Exp Pharmacol. 2011; (204): 1-46.
  36. Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology. 2013; 64: 215-23.
  37. Smith S, Toolan D, Kandebo M, et al. Preclinical Evaluation of MK-8189: A Novel Phosphodiesterase 10A Inhibitor for the Treatment of Schizophrenia. J Pharmacol Exp Ther. 2024. doi:10.1124/jpet.124.002347.
  38. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci 1999; 96: 7071–76.
  39. Stahl SM. Stahl’s essencial psychopharmacology. Neuroscientific basis and practical applications. Oxford University Press, Cambridge 2021.
  40. Stangherlin A, Zaccolo M. Phosphodiesterases and subcellular compartmentalized cAMP signaling in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2012; 302: H379-90.
  41. Suzuki K, Kimura H. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. CNS Neurosci Ther. 2018; 24 (7): 604-614.
  42. Świerczek A, Jankowska A, Chłoń-Rzepa G, Pawłowski M, Wyska E. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia. Curr Drug Targets. 2019; 20: 1652-69.
  43. Uliana DL, Martinez A, Grace AA. THPP-1 PDE10A inhibitor reverses the cognitive deficits and hyperdopaminergic state in a neurodevelopment model of schizophrenia. Schizophr Res. 2024; 274: 315-326.
  44. Wojtasik-Bakalarz K, Siwek M. New antipsychotic medication. Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii 2023, 39 (1), 19-38.
  45. Yin J, Chen KM, Clark MJ, Hijazi M, Kumari P, et al. Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane. Nature. 2020; 584: 125-29.
  46. Zagorska A, Partyka A, Bucki A, Gawalska A, Czopek A, et al. Phosphodiesterase 10 Inhibitors – Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery. Curr Med Chem. 2018; 25: 3455-81.
  47. Zhu J, Mix E, Winblad B. The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev. 2001; 7: 387-98.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications